A BRAF‐V600E antibody has recently been commercialized (Capper et al., 2011; Colomba et al., 2013; Ritterhouse & Barletta, 2015), and it is sensitive and specific in detecting BRAF‐V600E mutation in cutaneous melanomas (Capper et al., 2011; Colomba et al., 2013; Long et al., 2013). The gene discussed is BRAF; the disease is cutaneous melanoma.